CA2605792A1 - Extended release formulations - Google Patents

Extended release formulations Download PDF

Info

Publication number
CA2605792A1
CA2605792A1 CA002605792A CA2605792A CA2605792A1 CA 2605792 A1 CA2605792 A1 CA 2605792A1 CA 002605792 A CA002605792 A CA 002605792A CA 2605792 A CA2605792 A CA 2605792A CA 2605792 A1 CA2605792 A1 CA 2605792A1
Authority
CA
Canada
Prior art keywords
extended release
granules
formulation
wax
mesh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002605792A
Other languages
English (en)
French (fr)
Inventor
Shubha Chungi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceuticals USA Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2605792A1 publication Critical patent/CA2605792A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002605792A 2005-04-25 2006-04-25 Extended release formulations Abandoned CA2605792A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67444405P 2005-04-25 2005-04-25
US60/674,444 2005-04-25
PCT/US2006/015373 WO2006116247A1 (en) 2005-04-25 2006-04-25 Extended release formulations

Publications (1)

Publication Number Publication Date
CA2605792A1 true CA2605792A1 (en) 2006-11-02

Family

ID=36698750

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002605792A Abandoned CA2605792A1 (en) 2005-04-25 2006-04-25 Extended release formulations

Country Status (9)

Country Link
US (1) US20060275367A1 (https=)
EP (1) EP1877040A1 (https=)
JP (1) JP2008539240A (https=)
AU (1) AU2006239838A1 (https=)
BR (1) BRPI0610257A2 (https=)
CA (1) CA2605792A1 (https=)
MX (1) MX2007013327A (https=)
RU (1) RU2007143556A (https=)
WO (1) WO2006116247A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007122636A1 (en) * 2006-04-25 2007-11-01 Panacea Biotec Ltd Pharmaceutical compositions containing long chain fatty acids as excipients as well as a process for manufacturing the same
AU2014201170B2 (en) * 2006-12-20 2015-09-24 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
AU2007335156A1 (en) * 2006-12-20 2008-06-26 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
EP1972336A1 (en) * 2007-03-19 2008-09-24 LEK Pharmaceuticals D.D. Hot-melt micropellets
CN102036656A (zh) * 2008-03-21 2011-04-27 米兰制药有限公司 含有蜡的缓释制剂
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
WO2014051443A1 (en) * 2012-09-27 2014-04-03 Mendoza Wendell G Method for producing extended-release potassium citrate wax matrix tablet
US10369108B2 (en) * 2013-03-15 2019-08-06 Mylan Laboratories, Inc. Hot melt granulation formulations of poorly water-soluble active agents
WO2022266311A1 (en) * 2021-06-16 2022-12-22 Summit Biomedical Imaging PARPi-FL FORMULATIONS
CN117100711A (zh) * 2022-05-16 2023-11-24 江苏万珺医药科技有限公司 一种含有盐酸曲唑酮的缓释片剂及其制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2489439A (en) * 1947-06-27 1949-11-29 Samuel M Taylor Record controlled printing machine
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
USRE34990E (en) * 1986-08-07 1995-07-04 Ciba-Geigy Corporation Oral therapeutic system having systemic action
CH668187A5 (de) * 1986-08-07 1988-12-15 Ciba Geigy Ag Therapeutisches system mit systemischer wirkung.
FI894611L (fi) * 1988-09-30 1990-03-31 May & Baker Ltd Granulaera farmaceutiska preparat.
US5169645A (en) * 1989-10-31 1992-12-08 Duquesne University Of The Holy Ghost Directly compressible granules having improved flow properties
TW209174B (https=) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5326570A (en) * 1991-07-23 1994-07-05 Pharmavene, Inc. Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine
JP2616252B2 (ja) * 1992-10-16 1997-06-04 日本新薬株式会社 ワックスマトリックスの製法
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
DE4423078B4 (de) * 1994-07-01 2005-01-13 Awd.Pharma Gmbh & Co. Kg Verfahren zur Herstellung einer Carbamazepin-Arzneiform mit verzögerter Wirkstofffreisetzung
US5980942A (en) * 1997-01-23 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release matrix tablet formulations of carbamazepine
US6296873B1 (en) * 1997-01-23 2001-10-02 Yissum Research Development Company Of The Hebrew University Of Jerusalem Zero-order sustained release delivery system for carbamazephine derivatives
DE19729487A1 (de) * 1997-07-10 1999-01-14 Dresden Arzneimittel Verfahren zur Herstellung von Wirkstoff-Zubereitungen mit kontrollierter Freisetzung aus einer Matrix
DE19747261A1 (de) * 1997-10-25 1999-04-29 Bayer Ag Osmotisches Arzneimittelfreisetzungssystem
IL125244A (en) * 1998-07-07 2002-12-01 Yissum Res Dev Co Pharmaceutical compositions containing low-melting waxes
US6378526B1 (en) * 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6162466A (en) * 1999-04-15 2000-12-19 Taro Pharmaceutical Industries Ltd. Sustained release formulation of carbamazepine
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
ITMI20012749A1 (it) * 2001-12-21 2003-06-21 Chiesi Farma Spa Procedimento per la preparazione mediante trattamento con microonde di composti di inclusione tra farmaco e ciclodestrine e prodotti ottenut
US6572889B1 (en) * 2002-03-07 2003-06-03 Noveon Ip Holdings Corp. Controlled release solid dosage carbamazepine formulations
NZ542303A (en) * 2003-03-14 2008-12-24 Nirmal Mulye A process for preparing sustained release tablets
US20040241234A1 (en) * 2003-06-02 2004-12-02 Alpharma, Inc. Controlled release press-coated formulations of water-soluble active agents
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20080075785A1 (en) * 2006-09-22 2008-03-27 San-Laung Chow Controlled release hydrogel formulation

Also Published As

Publication number Publication date
US20060275367A1 (en) 2006-12-07
JP2008539240A (ja) 2008-11-13
AU2006239838A1 (en) 2006-11-02
WO2006116247A1 (en) 2006-11-02
BRPI0610257A2 (pt) 2010-06-08
RU2007143556A (ru) 2009-06-10
MX2007013327A (es) 2008-04-21
EP1877040A1 (en) 2008-01-16

Similar Documents

Publication Publication Date Title
TWI682789B (zh) 控釋藥物組合物及其製備方法
CN100579514C (zh) 通过受控制的凝聚而制备颗粒物的方法以及提高生物利用度的方法
EP3705118B1 (en) Oral solid dosage form composition having improved disintegration and preparation method therefor
ES2281313T3 (es) Composiciones farmacéuticas que comprenden lercanidipino
US20190083403A1 (en) Orally Disintegrating Tablet Formulation For Enhanced Bioavailability
EP3823597A2 (en) Multiparticulate formulations of cannabinoids
JP2010504950A (ja) 医薬組成物
CN104825397A (zh) 含有机溶胶涂层的受控释放递送物件
JP2007509155A (ja) クエチアピンを含有する薬剤
WO1995013794A1 (en) Process for producing stable medicinal composition, and pharmaceutical preparation
US20060275367A1 (en) Extended release formulations
TW200528144A (en) Controlled release of topiramate in liquid dosage forms
JPWO2005102291A1 (ja) 水溶性活性成分含有シームレスカプセル
CA2993612A1 (en) Methods of treatment using cadotril compositions
US7198803B2 (en) Sustained release oral preparations
EP2392318A1 (en) A pharmaceutical controlled release composition of losartan
TW201904572A (zh) 非布司他控釋組合物及其製備方法
WO2013032185A1 (ko) 프레가발린을 포함하는 서방성 제제
WO2011050944A1 (en) Formulations containing celecoxib
CN100551363C (zh) 包含贝特的固体剂型
US20130259935A1 (en) Pharmaceutical compositions comprising glimepiride and polyethylene glycol castor oil
EP4385500A1 (en) Fixed dose combination comprising netupitant and palonosetron
EP4385497A1 (en) Antioxidant-free fixed dose combination of netupitant and palonosetron
WO2024126398A1 (en) Fixed dose combination comprising netupitant and palonosetron
WO2024126408A1 (en) Antioxidant-free fixed dose combination of netupitant and palonosetron

Legal Events

Date Code Title Description
FZDE Discontinued